BioVaxys Technology Corp. announced that it has received a Notice of Allowance from the Japanese Patent Office for a Patent for inducing an antibody immune response from a low dose volume delivery of a B-cell epitope formulated with DPX. This Patent was part of the extensive Intellectual Property portfolio recently acquired by BioVaxys from the former IMV Inc. This Patent has already been issued in the US, and is currently pending in the EU.

DPX is a proprietary lipid-based delivery platform with no aqueous component that can be formulated with a range of packaged antigens, proteins, peptides, mRNA, or small molecules. Its unique no release mechanism of action allows antigen presenting cells (APCs) to be attracted to the injection site, facilitating a robust and sustained immune response. The smallest dose of a currently approved vaccine is 0.1ml for Sanofi-Pasteur's Fluzone Intradermal Quadrivalent vaccine.

Low dose volume delivery of DPX? formulated B-cell epitope is designed to be delivered in single dose as low as 50µL to 90 µL. An epitope is the part of an antigen that the host's immune system recognizes, eliciting the immune response to an invading pathogen. It specifically binds to the corresponding antigen receptor on the immune cell (such as a B-cell).

Whereas T-cells protect people from getting infected by destroying cancerous and infected cells, B-cells produce antibodies to fight infection. Having an ability to create low dose DPX?+B cell epitope formulations is an attractive approach for packaging antigens for cancer immunotherapeutics and therapeutic vaccines such as for influenza, Zika virus, RSV, HSV, and many other viral or bacterial pathogens. BioVaxys also announced that it filed an international patent application through the Patent Cooperation Treaty (PCT) from two pending patent applications in the US related to methods of formulating DPX?

compositions that comprise both a lipid-based adjuvant (i.e. PAM) and a polyI:C polynucleotide adjuvant.